New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients

Cam upepimut is an experimental vaccine designed to train immune cells to recognize seven common mutations in KRAS, a gene altered in about 90 percent of pancreatic ductal adenocarcinomas. The randomized phase 2 trial enrolled 144 people treated with surgery and chemotherapy for KRAS-mutated pancreatic cancer, all without visible disease on scans at the start. Ninety-six received the vaccine and 48 were controls. Among the 90 vaccinated participants whose immune responses could be measured, 98.9 percent developed stronger T-cell responses to mutated KRAS; for more than 80 percent, responses rose more than ninefold from before vaccination.

The results establish that the vaccine can provoke a targeted immune response, but they do not show that it prevents cancer from returning. Researchers found no statistically significant difference in disease-free survival between the vaccine and control groups. An exploratory analysis suggested that patients with stronger vaccine responses had longer disease-free periods, offering a reason for further study rather than proof of benefit. The vaccine appears to reach lymph nodes and alter immune activity, and a planned phase 3 trial will test additional booster doses and may examine combinations with other treatments. The findings matter because pancreatic cancer often recurs after treatment and has been difficult to treat with immunotherapy, but whether this approach improves outcomes remains unresolved.